Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Renal and urinary disorders – page 14

  • 580 clinical trials
  • 226 recruiting
  • 296 conditions
  • 27 countries

Conditions in this area

296 conditions with trials, the busiest first

Chronic kidney disease61Bladder cancer54Transitional cell carcinoma46Renal cell carcinoma42Bladder transitional cell carcinoma33IgA nephropathy23Acute kidney injury21Non-small cell lung cancer19Lupus nephritis18Clear cell renal cell carcinoma17Urinary tract infection17Paroxysmal nocturnal haemoglobinuria16Breast cancer14Metastatic renal cell carcinoma14End stage renal disease13Congenital cystic kidney disease12Colorectal cancer11Endometrial cancer11Hepatocellular carcinoma11Malignant melanoma11Nephrotic syndrome11Ovarian cancer11Glomerulonephritis membranous10Kidney transplant rejection10+272

Clinical trials in Renal and urinary disorders

580 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

580 clinical trials

Hyperparathyroidism secondary

Recruiting

Study of alfacalcidol for treating secondary hyperparathyroidism in patients after gastric bypass surgery

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alfacalcidol
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Lupus nephritis

Recruiting

Study of Obinutuzumab and Mycophenolate Mofetil Without Oral Corticosteroids for Treatment of Lupus Nephritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Urinary tract infection

Recruiting

Study of Intravenous Fosfomycin, Tazobactam Sodium, and Ertapenem Sodium for Hospitalized Patients with Complicated Urinary Tract Infections

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ertapenem Sodium
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

Renal cancer+2

Recruiting

Study on Using EMI-137 for Intraoperative Visualization in Patients with Penile and Tongue Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ac-Ala-Gly-Ser-Cys(1)-Tyr-Cys(2)-Ser-Gly-Pro-Pro-Arg-Phe-Glu-Cys(2)-Trp-Cys(1)-Tyr-Glu-Thr-Glu-Gly-Thr-Gly-Gly-Gly-Lys(Unk)-Nh2 Conjugated To Cy5 Dye
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Atypical haemolytic uraemic syndrome

Recruiting

Study of Eculizumab in Adults with Hypertensive Emergency-Related Hemolytic Uremic Syndrome Requiring Dialysis or with Severe Kidney Problems

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Eculizumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Lupus nephritis

Recruiting

Study on the Safety and Effectiveness of MSV-allo for Patients with Lupus Nephritis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Msv-Allo
  • Sponsor:Hospital Universitario Rio Hortega

Chronic kidney disease

Recruiting

Study on Patiromer for Improving RAAS Treatment in Patients with Chronic Kidney Disease Stages 3b/4

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Hydrochlorothiazide
  • Sponsor:Universitair Medisch Centrum Groningen

Atypical haemolytic uraemic syndrome

Recruiting

Study on Switching from Anti-C5 Antibody Therapy to Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Alport's syndrome

Recruiting

Study on Dapagliflozin for Slowing Kidney Disease in Adolescents and Young Adults with Alport Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Dapagliflozin
  • Sponsor:Universitaetsmedizin Goettingen

Bladder transitional cell carcinoma+3

Recruiting

Study on Hexaminolevulinate for Patients with Non-Muscle Invasive Bladder Cancer to Reduce Need for Second Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Hexaminolevulinate
  • Sponsor:Universita Degli Studi Di Roma La Sapienza

Bladder transitional cell carcinoma

Recruiting

Study of Cabozantinib and Durvalumab for Patients with Advanced Bladder Cancer After Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Metastatic renal cell carcinoma

Recruiting

Study of Axitinib and Nivolumab for Patients with Metastatic Renal Cell Carcinoma Not Responding Completely to Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Consorzio Oncotech

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab52 clinical trialsNivolumab36 clinical trialsMycophenolate Mofetil24 clinical trialsDapagliflozin23 clinical trialsCabozantinib22 clinical trialsCisplatin22 clinical trialsIpilimumab21 clinical trialsGemcitabine20 clinical trialsSodium Chloride17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.